Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer

PaperCitations, authors & open-access status

T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 29 citations, 2017 year and bronze oa status.

29
Citations
2017
Year
bronze
OA Status

Related on ScholarIQ

Satomi Watanabe
Author
Lung Cancer Treatments and Mutations
Topic
Lung Cancer Treatments and Mutations
Topic
Cancer therapeutics and mechanisms
Topic
PI3K/AKT/mTOR signaling in cancer
Topic
470M+ articles · free account